<DOC>
	<DOCNO>NCT00079378</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine valproic acid treat patient refractory relapse acute myeloid leukemia previously treat chronic lymphocytic leukemia small lymphocytic leukemia . Drugs use chemotherapy , decitabine , work different way stop cancer cell divide stop grow die . Valproic acid may stop growth cancer cell block enzymes necessary growth . Combining decitabine valproic acid may kill cancer cell .</brief_summary>
	<brief_title>Decitabine Valproic Acid Treating Patients With Refractory Relapsed Acute Myeloid Leukemia Previously Treated Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine minimally effective pharmacological dose ( MEPD ) decitabine patient refractory relapse acute myeloid leukemia previously treat chronic lymphocytic lymphoma small lymphocytic lymphoma . II . Determine maximum tolerate dose ( MTD ) valproic acid combination MEPD decitabine patient . III . Determine MEPD valproic acid combination decitabine patient . IV . Determine qualitative quantitative toxic effect decitabine alone combination valproic acid , term organ specificity , time course , predictability , reversibility patient . SECONDARY OBJECTIVES : I . Determine therapeutic response patient treated decitabine alone combination valproic acid . II . Determine pharmacokinetics regimen patient . III . Determine kinetics methyltransferase activity re-expression select target gene AML [ p15 , estrogen receptor ( ER ) , WT-1 , calcitonin , MYOD1 ] CLL/SLL [ DERMO-1 , DAPK , ID4 ] know methylated primary tumor cell . IV . Correlate baseline post-treatment change DNA methyltransferases ( MT1 , MT3a , MT3b ) expression achievement decitabine MEPD , toxicity , treatment resistance , disease response patient . V. Determine kinetics HDAC enzyme inhibition change acetylation status histone H3 H4 follow treatment combination . These parameter use define MEPD combination . VI . Examine baseline post-therapy change `` histone code ' AML CLL cell assessment acetylation methylation status histone H3 H4 lysine residue use Western Blot Mass Spectrometry technique . OUTLINE : This dose-escalation study . Patients stratify accord disease ( refractory relapse acute myeloid leukemia v chronic lymphocytic leukemia small lymphocytic lymphoma ) . Patients receive decitabine IV 1 hour day 1-5 1-10 . Treatment repeat every 28 day . Cohorts 6 patient receive escalate dos decitabine minimally effective pharmacological dose ( MEPD ) determine . The MEPD define dose least 5 6 patient meet gene methylation criterion 1 6 patient experience dose-limiting toxicity ( DLT ) . Once MEPD determine , patient receive decitabine dose level administer oral valproic acid three time daily day 5-21 . Treatment repeat every 28 day . Cohorts 3-6 patient receive escalate dos valproic acid maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience DLT . The MEPD valproic acid determine use establish gene methylation toxicity criterion . Treatment continue 24 month absence disease progression unacceptable toxicity . Patients follow survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients AML ( Stratum I ) CLL/SLL ( Stratum II ) enrol Patients stratum I one follow : Primary refractory relapse ( 1 year less ) disease candidate potentially curative therapy Untreated AML patient candidate chemotherapy Patients stratum I must normal WBC ( = &lt; 10 x 10^9/L ) WBC = &lt; 40 x 10^9/L stable 1 week ( may sustain hydroxyurea prior start therapy first 4 day therapy clinically indicate ) Patients stratum II receive least one prior therapy CLL/SLL include purine analog ; patient stratum II history severe autoimmune disease require therapy chronic corticosteroid specific relative contraindication receive purine analog , therefore , receive another form therapy include alkylating agent eligible participate Performance status ECOG 02 At least 12 week life expectancy Stratum II : No uncontrolled autoimmune hemolytic anemia No idiopathic thrombocytopenia purpura Bilirubin = &lt; 1.5 mg/dL ALT AST = &lt; 2 time upper limit normal Creatinine = &lt; 2.0 mg/dL No active infection require IV antibiotic HIV negative No severe medical condition would preclude study participation No psychiatric condition would preclude study compliance No history seizures Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception More 14 day since prior chemotherapy ( except hydroxyurea ) No prior FR901228 ( depsipeptide ) step 2 study No concurrent chemotherapy No concurrent corticosteroid antiemetic therapy No concurrent hormonal therapy except follow : Steroids treatment adrenal failure septic shock Insulin diabetes Tamoxifen equivalent breast cancer prevention adjuvant therapy Estrogens progestins gynecologic indication More 14 day since prior radiotherapy No concurrent palliative radiotherapy No concurrent anticonvulsant medication , include valproic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>